Literature DB >> 3498002

Interleukin 4 (B cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells.

J J Mulé, C A Smith, S A Rosenberg.   

Abstract

Interleukin 4 (IL-4) expresses multiple biologic activities, including B cell, mast cell, and T cell stimulation. We showed that the incubation of resting splenocytes from C57BL/6 mice solely in purified native or recombinant mouse IL-4 results in the generation of lymphokine-activated killer (LAK) activity directed against fresh, syngeneic sarcoma cells. The precursor activated by IL-4 expresses surface asialo-GM1. In addition, IL-4 is capable of amplifying the splenic LAK activity induced by recombinant IL-2. The generation, by IL-4, of killer cells with broad antitumor reactivity raises the possibility of using IL-4 alone or in combination with IL-2 in the immunotherapy of cancer in animal models.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3498002      PMCID: PMC2188702          DOI: 10.1084/jem.166.3.792

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  14 in total

1.  Increased expression of Ia antigens on resting B cells: an additional role for B-cell growth factor.

Authors:  R Noelle; P H Krammer; J Ohara; J W Uhr; E S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  1984-10       Impact factor: 11.205

Review 2.  Interleukin 2.

Authors:  K A Smith
Journal:  Annu Rev Immunol       Date:  1984       Impact factor: 28.527

3.  Cloning of cDNA encoding the murine IgG1 induction factor by a novel strategy using SP6 promoter.

Authors:  Y Noma; P Sideras; T Naito; S Bergstedt-Lindquist; C Azuma; E Severinson; T Tanabe; T Kinashi; F Matsuda; Y Yaoita
Journal:  Nature       Date:  1986 Feb 20-26       Impact factor: 49.962

4.  Biological activity of recombinant human interleukin-2 produced in Escherichia coli.

Authors:  S A Rosenberg; E A Grimm; M McGrogan; M Doyle; E Kawasaki; K Koths; D F Mark
Journal:  Science       Date:  1984-03-30       Impact factor: 47.728

5.  Interleukin 2 dependence of human natural killer (NK) cell activity.

Authors:  W Domzig; B M Stadler; R B Herberman
Journal:  J Immunol       Date:  1983-04       Impact factor: 5.422

6.  In vivo interleukin 2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells.

Authors:  S H Hefeneider; P J Conlon; C S Henney; S Gillis
Journal:  J Immunol       Date:  1983-01       Impact factor: 5.422

7.  A T cell activity that enhances polyclonal IgE production and its inhibition by interferon-gamma.

Authors:  R L Coffman; J Carty
Journal:  J Immunol       Date:  1986-02-01       Impact factor: 5.422

8.  Characterization of a murine lymphokine distinct from interleukin 2 and interleukin 3 (IL-3) possessing a T-cell growth factor activity and a mast-cell growth factor activity that synergizes with IL-3.

Authors:  C A Smith; D M Rennick
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

9.  Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2.

Authors:  J J Mulé; S Shu; S L Schwarz; S A Rosenberg
Journal:  Science       Date:  1984-09-28       Impact factor: 47.728

10.  Interleukin-induced increase in Ia expression by normal mouse B cells.

Authors:  N W Roehm; H J Leibson; A Zlotnik; J Kappler; P Marrack; J C Cambier
Journal:  J Exp Med       Date:  1984-09-01       Impact factor: 14.307

View more
  26 in total

1.  Partial correction of defective generation of lymphokine-activated killer cells in patients with chronic myelogenous leukaemia after in vivo treatment with interferon-alpha (Wellferon).

Authors:  G Pawelec; E Schneider; G Ehninger; A Rehbein; H Schmidt
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Heterogeneous lymphokine-activated killer cell precursor populations. Development of a monoclonal antibody that separates two populations of precursors with distinct culture requirements and separate target-recognition repertoires.

Authors:  B A Fox; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 3.  Lymphokine activated killer cells.

Authors:  A Lindemann; F Herrmann; W Oster; R Mertelsmann
Journal:  Blut       Date:  1989-10

4.  IL-3 and IL-4 affect thymocyte differentiation in organ culture.

Authors:  P M Wood; R K Jordan; A L Givan; C G Brooks
Journal:  Immunology       Date:  1990-09       Impact factor: 7.397

5.  In vivo treatment with interferon causes augmentation of IL-2 induced lymphokine-activated killer cells in the organs of mice.

Authors:  R K Puri; P Leland
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

6.  Interleukin-3 and interleukin-4 each strongly inhibit the induction and function of human LAK cells.

Authors:  G Gallagher; F Wilcox; F al-Azzawi
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

7.  Human recombinant IL-4 suppresses the induction of human IL-2 induced lymphokine activated killer (LAK) activity.

Authors:  B Brooks; R C Rees
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

8.  In vitro and in vivo growth of B16F10 melanoma cells transfected with interleukin-4 cDNA and gene therapy with the transfectant.

Authors:  T Ohira; Y Ohe; Y Heike; E R Podack; K J Olsen; K Nishio; M Nishio; Y Miyahara; Y Funayama; H Ogasawara
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

9.  Human recombinant IL-4 decreases the emergence of non-specific cytolytic cells and favours the appearance of memory cells (CD4+CD45RO+) in the IL-2-driven development of cytotoxic T lymphocytes against autologous ovarian tumour cells.

Authors:  A D Roth; S Dupuis; P Alberto
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

Review 10.  Cytokine-mediated gene therapy for cancer.

Authors:  A R Miller; W H McBride; K Hunt; J S Economou
Journal:  Ann Surg Oncol       Date:  1994-09       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.